[{"id":"360b90be-2213-4d23-b6e5-cc0f96b7a6e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04238715","created_at":"2021-01-19T19:12:02.961Z","updated_at":"2025-02-25T14:40:28.907Z","phase":"Phase 2","brief_title":"A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion","source_id_and_acronym":"NCT04238715","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-14"},{"id":"9d94409b-3124-4594-8d29-7cfddaf92a43","acronym":"FOENIX-CCA4","url":"https://clinicaltrials.gov/study/NCT05727176","created_at":"2023-02-14T18:02:28.005Z","updated_at":"2025-02-25T17:02:23.376Z","phase":"Phase 2","brief_title":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","source_id_and_acronym":"NCT05727176 - FOENIX-CCA4","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-03"},{"id":"ef460ada-1956-4c98-ae47-6b4d433dca90","acronym":"ReFocus","url":"https://clinicaltrials.gov/study/NCT04526106","created_at":"2021-01-18T21:40:34.651Z","updated_at":"2025-02-25T17:30:23.437Z","phase":"Phase 1/2","brief_title":"REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors","source_id_and_acronym":"NCT04526106 - ReFocus","lead_sponsor":"Elevar Therapeutics","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lirafugratinib (RLY-4008)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/27/2024","primary_completion_date":" 09/27/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-01-30"},{"id":"678c2f57-c2a1-4d53-9b3f-1c28268db167","acronym":"","url":"https://clinicaltrials.gov/study/NCT05174650","created_at":"2022-01-03T15:00:36.712Z","updated_at":"2025-02-25T13:36:03.205Z","phase":"Phase 2","brief_title":"Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements","source_id_and_acronym":"NCT05174650","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • derazantinib (ARQ 087)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-07-24"},{"id":"e9547fb4-4cd2-4f5f-b4e3-ae7528896751","acronym":"FIRST-308","url":"https://clinicaltrials.gov/study/NCT05948475","created_at":"2023-07-17T14:08:53.898Z","updated_at":"2024-07-02T16:34:27.046Z","phase":"Phase 3","brief_title":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","source_id_and_acronym":"NCT05948475 - FIRST-308","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • tinengotinib (TT-00420)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/20/2023","start_date":" 12/20/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-12"},{"id":"f1eb15be-99b0-4993-89d8-1f3e74e59506","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297903","created_at":"2022-03-28T13:52:59.235Z","updated_at":"2024-07-02T16:35:05.357Z","phase":"Phase 2","brief_title":"XmAb20717 in Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT05297903","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" FGFR2 • IDH1 • NTRK","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion","tags":["FGFR2 • IDH1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"e391f2a5-896d-4821-b066-fdd97cba862d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919642","created_at":"2021-06-10T01:52:34.634Z","updated_at":"2024-07-02T16:35:07.347Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","source_id_and_acronym":"NCT04919642","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-26"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"},{"id":"b2993259-256a-4604-9f68-777de564f0ad","acronym":"FOENIX-CCA2","url":"https://clinicaltrials.gov/study/NCT02052778","created_at":"2021-01-17T17:33:24.806Z","updated_at":"2024-07-02T16:35:13.841Z","phase":"Phase 1/2","brief_title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02052778 - FOENIX-CCA2","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Completed","enrollment":" Enrollment 407","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 05/29/2021","study_completion_date":" 05/29/2021","last_update_posted":"2024-03-20"},{"id":"116e49b9-25ff-4c8b-8c1c-a81e2d73d438","acronym":"","url":"https://clinicaltrials.gov/study/NCT05678270","created_at":"2023-01-10T14:58:55.552Z","updated_at":"2024-07-02T16:35:20.602Z","phase":"Phase 2","brief_title":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT05678270","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gunagratinib (ICP-192)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-07"},{"id":"1f885c20-bddc-441e-b3b3-ce916b0c4eaf","acronym":"FIGHT-209","url":"https://clinicaltrials.gov/study/NCT05267106","created_at":"2022-03-04T15:53:30.724Z","updated_at":"2024-07-02T16:35:22.897Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","source_id_and_acronym":"NCT05267106 - FIGHT-209","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-01-19"},{"id":"2354d741-07d7-4fa3-9724-54f92f01122f","acronym":"FORTUNE","url":"https://clinicaltrials.gov/study/NCT04962867","created_at":"2021-07-15T13:06:08.522Z","updated_at":"2025-02-25T13:35:52.987Z","phase":"Phase 2","brief_title":"NCCH2006/MK010 Trial (FORTUNE Trial)","source_id_and_acronym":"NCT04962867 - FORTUNE","lead_sponsor":"National Cancer Center, Japan","biomarkers":" EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation","tags":["EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-08"},{"id":"45f9e4a5-fb7c-4d84-a994-fb30e1410536","acronym":"FIDES-01","url":"https://clinicaltrials.gov/study/NCT03230318","created_at":"2021-01-17T17:21:24.827Z","updated_at":"2025-02-25T13:34:55.963Z","phase":"Phase 2","brief_title":"Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT03230318 - FIDES-01","lead_sponsor":"Basilea Pharmaceutica","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e derazantinib (ARQ 087)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2023-12-19"},{"id":"2b64af10-d65b-4d9e-b123-5cd01fb9300a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627063","created_at":"2022-11-25T15:58:10.134Z","updated_at":"2024-07-02T16:35:38.335Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05627063","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK121"],"overall_status":"Recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-09-01"},{"id":"1cfd7d2e-e8fc-43e3-8ada-87dc26bcb0d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565794","created_at":"2022-10-04T13:56:42.746Z","updated_at":"2024-07-02T16:35:38.853Z","phase":"Phase 2","brief_title":"Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements","source_id_and_acronym":"NCT05565794","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" FGFR2 • CD4","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-08-28"},{"id":"af3308c0-744c-4b7e-92d9-8816339110ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05510427","created_at":"2022-08-22T13:04:20.402Z","updated_at":"2024-07-02T16:35:40.025Z","phase":"Phase 1","brief_title":"Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification","source_id_and_acronym":"NCT05510427","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FGFR2 • CD4","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Truseltiq (infigratinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":" Primary completion: 08/07/2023","primary_completion_date":" 08/07/2023","study_txt":" Completion: 08/07/2023","study_completion_date":" 08/07/2023","last_update_posted":"2023-08-15"},{"id":"913fa15c-9288-4cf0-a89a-f0851bfabf86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04353375","created_at":"2023-07-06T20:09:42.965Z","updated_at":"2025-02-25T14:51:46.214Z","phase":"Phase 2","brief_title":"Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT04353375","lead_sponsor":"Hutchmed","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-07-06"},{"id":"f3f16916-e4d8-4dd3-86eb-e3bd81122724","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913661","created_at":"2023-06-22T19:11:39.305Z","updated_at":"2024-07-02T16:35:45.040Z","phase":"Phase 2","brief_title":"Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT05913661","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-06-22"},{"id":"7712e249-c771-42c3-9329-6505eef60157","acronym":"","url":"https://clinicaltrials.gov/study/NCT01752920","created_at":"2021-01-18T07:41:42.842Z","updated_at":"2025-02-25T16:12:56.841Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations","source_id_and_acronym":"NCT01752920","lead_sponsor":"Basilea Pharmaceutica","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e derazantinib (ARQ 087)"],"overall_status":"Completed","enrollment":" Enrollment 119","initiation":"Initiation: 12/10/2012","start_date":" 12/10/2012","primary_txt":" Primary completion: 08/28/2018","primary_completion_date":" 08/28/2018","study_txt":" Completion: 08/28/2018","study_completion_date":" 08/28/2018","last_update_posted":"2023-06-05"},{"id":"89ca258d-eb1d-40cf-a834-fa6461b873b5","acronym":"FIGHT-202","url":"https://clinicaltrials.gov/study/NCT02924376","created_at":"2021-01-17T17:17:39.386Z","updated_at":"2024-07-02T16:35:54.862Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)","source_id_and_acronym":"NCT02924376 - FIGHT-202","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 rearrangement","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 01/16/2017","start_date":" 01/16/2017","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2023-02-23"},{"id":"934d3478-921a-4635-9f03-493d15ba270a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05244551","created_at":"2022-02-17T18:22:17.151Z","updated_at":"2024-07-02T16:36:00.316Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05244551","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2022-11-16"},{"id":"059be10f-2a45-47c2-978f-ca17df6ee6cf","acronym":"ICP-CL-00301","url":"https://clinicaltrials.gov/study/NCT03758664","created_at":"2021-01-18T18:28:29.537Z","updated_at":"2024-07-02T16:36:07.705Z","phase":"Phase 1/2","brief_title":"Clinical Study of ICP-192 in Solid Tumors Patients","source_id_and_acronym":"NCT03758664 - ICP-CL-00301","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 translocation","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gunagratinib (ICP-192)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-07-06"},{"id":"c7ffedfa-b221-47a0-8188-045db5ae4afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02691793","created_at":"2021-01-18T13:07:48.373Z","updated_at":"2024-07-02T16:36:08.891Z","phase":"Phase 4","brief_title":"Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02691793","lead_sponsor":"Samsung Medical Center","biomarkers":" RET • FGFR2","pipe":" | ","alterations":" RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive","tags":["RET • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 11/20/2017","start_date":" 11/20/2017","primary_txt":" Primary completion: 08/30/2019","primary_completion_date":" 08/30/2019","study_txt":" Completion: 11/19/2019","study_completion_date":" 11/19/2019","last_update_posted":"2022-06-15"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"}]